The specificity of proteasomes: Impact on MHC class I processing and presentation of antigens

Immunological Reviews

Volumn 172, Issue , 1999, Pages 29-48

  Niedermann, Gabriele ^a   Geier, Elke ^a   Lucchiari Hartz, Maria ^a   Hitziger, Niclas ^a   Ramsperger, Arne ^a   Eichmann, Klaus ^a  

^a MAX PLANCK INSTITUTE OF IMMUNOBIOLOGY AND EPIGENETICS   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; PROTEASOME;

ANIMAL CELL; ANTIGEN PRESENTATION; ARTICLE; CYTOTOXIC T LYMPHOCYTE; EUKARYOTIC CELL; HUMAN; HUMAN CELL; MAJOR HISTOCOMPATIBILITY COMPLEX; MOLECULAR EVOLUTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION;

EID: 0033452325     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-065X.1999.tb01354.x     Document Type: Article

References (96)

1. 1. Coux O, Tanaka K, Goldberg AL. Structure and functions of the 20S and 26S proteasomes. Annu Rev Biochem 1996;65:801-847.
2. 2. Hershko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem 1998;67:425-479.
3. 3. Baumeister W, Walz J, Zuhl F, Seemüller E. The proteasome: paradigm of a self-compartmentalizing protease. Cell 1998;92:367-380.
4. 4. Tanaka K, Kasahara M. The MHC class I ligand-generating system: roles of immunoproteasomes and the interferon-γ-inducible proteasome activator PA28. Immunol Rev 1998;163:161-176.
5. 5. Tanaka K, Tanahashi N, Tsurumi C, Yokota KY, Shimbara N. Proteasomes and antigen processing. Adv Immunol 1997;64:1-38.
6. 6. Schechter I, Berger A. On the active site of proteases. 3. Mapping the active site of papain; specific peptide inhibitors of papain. Biochem Biophys Res Commun 1968;32:898-902.
7. 7. Deng Y, Yewdell JW, Eisenlohr LC, Bennink JR. MHC affinity, peptide liberation, T cell repertoire, and immunodominance all contribute to the paucity of MHC class I-restricted peptides recognized by antiviral CTL. J Immunol 1997;158:1507-1515.
8. 8. Yewdell JW, Bennink JR. Immunodominance in MHC class I-restricted T lymphocyte responses. Annu Rev Immunol 1999;17:1-30.
9. 9. Chen W, Khilko S, Fecondo J, Margulies DH, McCluskey J. Determinant selection of major histocompatibility complex class I-restricted antigenic peptides is explained by class I-peptide affinity and is strongly influenced by nondominant anchor residues. J Exp Med 1994;180:1471-1483.
10. 10. Niedermann G, et al. Contribution of proteasome-mediated proteolysis to the hierarchy of epitopes presented by major histocompatibility complex class I molecules. Immunity 1995;2:289-299.
11. b-restricted ovalbumin peptide and an assessment of the predictive power of MHC-binding motifs. Eur J Immunol 1992;22:2663-2667.
12. b binding motif. J Immunol 1993;150:1212-1222.
13. 13. Dick LR, et al. Proteolytic processing of ovalbumin and β-galactosidase by the proteasome to yield antigenic peptides. J Immunol 1994;151:3884-3894.
14. 14. Niedermann G, et al. The proteolytic fragments generated by vertebrate proteasomes: structural relationships to major histocompatibility complex class I binding peptides. Proc Natl Acad Sci USA 1996;93:8572-8577.
15. 15. Ossendorp F, et al. A single residue exchange within a viral CTL epitope alters proteasome-mediated degradation resulting in lack of antigen presentation. Immunity 1996;5:115-124.
16. 16. Valmori D, et al. Modulation of proteasomal activity required for the generation of a cytotoxic T lymphocyte-defined peptide derived from the tumor antigen MAGE-3. J Exp Med 1999;189:895-905.
17. 17. Yellen-Shaw AJ, Wherry EJ, Dubois GC, Eisenlohr LC. Point mutation flanking a CTL epitope ablates in vitro and in vivo recognition of a full-length viral protein. J Immunol 1997;158:3227-3234.
18. 18. Anton LC, Yewdell JW, Bennink JR. MHC class I-associated peptides produced from endogenous gene products with vastly different efficiencies. J Immunol 1997;158:2535-2542.
19. 19. Dick TP, et al. Contribution of proteasomal β-subunits to the cleavage of peptide substrates analyzed with yeast mutants. J Biol Chem 1998;273:25637-25646.
20. 20. Groettrup M, et al. A role for the proteasome regulator PA28α in antigen presentation. Nature 1996;381:166-168.
21. 21. Del Val M, Schlicht HJ, Ruppert T, Reddehase MJ, Koszinowski UH. Efficient processing of an antigenic sequence for presentation by MHC class I molecules depends on its neighboring residues in the protein. Cell 1991;66:1145-1153.
22. 22. Eisenlohr LC, Yewdell JW, Bennink JR. Flanking sequences influence the presentation of an endogenously synthesized peptide to cytotoxic T lymphocytes. J Exp Med 1992;175:481-487.
23. 23. Bergmann CC, Tong L, Cua R, Sensintaffar J, Stohlman S. Differential effects of flanking residues on presentation of epitopes from chimeric peptides. J Virol 1994;68:5306-5310.
24. + T cell recognition of an endogenously processed epitope is regulated primarily by residues within the epitope. J Exp Med 1992;176:1335-1341.
25. 25. Eggers M, Boes-Fabian B, Ruppert T, Kloetzel PM, Koszinowski UH. The cleavage preference of the proteasome governs the yield of antigenic peptides. J Exp Med 1995;182:1865-1870.
26. 26. Bergmann CC, Yao Q, Ho CK, Buckwold SL. Flanking residues alter antigenicity and immnnogenicity of multi-unit CTL epitopes. J Immunol 1996;157:3242-3249.
27. 27. Theobald M, et al. The sequence alteration associated with mutational hotspot in p53 protects cells from lysis by cytotoxic T lymphocytes specific for a flanking peptide epitope. J Exp Med 1998;188:1017-1028.
28. 28. Chimini G, Pala P, Sire J, Jordan BR, Maryanski JL. Recognition of oligonucleotide-encoded T cell epitopes introduced into a gene unrelated to the original antigen. J Exp Med 1989;169:297-302.
29. 29. Hahn YS, Braciale VL, Braciale TJ. Presentation of viral antigen to class I major histocompatibility complex-restricted cytotoxic T lymphocyte. Recognition of an immunodominant influenza hemagglutinin site by cytotoxic T lymphocyte is independent of the position of the site in the hemagglutinin translation product. J Exp Med 1991;174:733-736.
30. b-restricted cytotoxic T-lymphocyte epitopes in simian virus 40 tumor antigen. J Virol 1995;69:3134-3146.
31. 31. Weidt G, Deppert W, Buchhop S, Dralle H, Lehmann-Grube F. Antiviral protective immunity induced by major histocompatibility complex class I molecule-restricted viral T-lymphocyte epitopes inserted in various positions in immunologically self and nonself proteins. J Virol 1995;69:2654-2658.
32. 32. Levitskaya J, et al. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature 1995;375:685-688.
33. 33. Sharipo A, Imreh M, Leonchiks A, Imreh S, Masucci MG. A minimal glycine-alanine repeat prevents the interaction of ubiquitinated I κB α with the proteasome: a new mechanism for selective inhibition of proteolysis. Nat Med 1998;4:939-944.
34. 34. Lin L, Ghosh S. A glycine-rich region in NF-κB p105 functions as a processing signal for the generation of the p50 subunit. Mol Cell Biol 1996;16:2248-2254.
35. 35. Wilk S, Orlowski M. Cation-sensitive neutral endopeptidase: isolation and specificity of the bovine pituitary enzyme. J Neurochem 1980;35:1172-1182.
36. 36. Orlowski M, Cardozo C, Michaud C. Evidence for the presence of five distinct proteolytic components in the pituitary multicatalytic proteinase complex. Properties of two components cleaving bonds on the carboxyl side of branched chain and small neutral amino acids. Biochemistry 1993;32:1563-1572.
37. 37. Heinemeyer W, Fischer M, Krimmer T, Stachon U, Wolf DH. The active sites of the eukaryotic 20 S proteasome and their involvement in subunit precursor processing. J Biol Chem 1997;272:25200-25209.
38. 38. McCormack TA, et al. Kinetic studies of the branched chain amino acid preferring peptidase activity of the 20S proteasome: development of a continuous assay and inhibition by tripeptide aldehydes and clastolactacystin β-lactone. Biochemistry 1998;37:7792-7800.
39. 39. Dick LR, Moomaw CR, DeMartino GN, Slaughter CA. Degradation of oxidized insulin B chain by the multiproteinase complex macropain (proteasome). Biochemistry 1991;30:2725-2734.
40. 40. Ehring B, Meyer TH, Eckerskorn C, Lottspeich F, Tampe R. Effects of major-histocompatibility-complex-encoded subunits on the peptidase and proteolytic activities of human 20S proteasomes. Cleavage of proteins and antigenic peptides. Eur J Biochem 1996;235:404-415.
41. 41. Cardozo C, Kohanski RA. Altered properties of the branched chain amino acid-preferring activity contribute to increased cleavages after branched chain residues by the "immunoproteasome". J Biol Chem 1998;273:16764-16770.
42. 42. Nussbaum AK, et al. Cleavage motifs of the yeast 20S proteasome β subunits deduced from digests of enolase 1. Proc Natl Acad Sci USA 1998;95:12504-12509.
43. 43. Orlowski M, Michaud C. Pituitary multicatalytic proteinase complex. Specificity of components and aspects of proteolytic activity. Biochemistry 1989;28:9270-9278.
44. 44. Cardozo C, Vinitsky A, Michaud C, Orlowski M. Evidence that the nature of amino acid residues in the P3 position directs substrates to distinct catalytic sites of the pituitary multicatalytic proteinase complex (proteasome). Biochemistry 1994;33:6483-6489.
45. 45. Vinitsky A, Cardozo C, Sepp-Lorenzino L, Michaud C, Orlowski M. Inhibition of the proteolytic activity of the multicatalytic proteinase complex (proteasome) by substrate-related peptidyl aldehydes. J Biol Chem 1994;269:29860-29866.
46. 46. Bogyo M, Shin S, McMaster JS, Ploegh HL. Substrate binding and sequence preference of the proteasome revealed by active-site-directed affinity probes. Chem Biol 1998;5:307-320.
47. 47. Holzhütter HG, Frömmel C, Kloetzel PM. A theoretical approach towards the identification of cleavage-determining amino acid motifs of the 20 S proteasome. J Mol Biol 1999;286:1251-1265.
48. 48. Wenzel T, Eckerskorn C, Lottspeich F, Baumeister W. Existence of a molecular ruler in proteasomes suggested by analysis of degradation products. FEBS Lett 1994;349:205-209.
49. 49. Dolenc I, Seemüller E, Baumeister W. Decelerated degradation of short peptides by the 20S proteasome. FEBS Lett 1998;434:357-361.
50. 50. Rammensee HG, Friede T, Stefanovic S. MHC ligand motifs: first listing. Immunogenetics 1995;41:178-228.
51. 51. Wallny HJ, Rötzschke O, Falk K, Hämmerling G, Rammensee HG. Gene transfer experiments imply instructive role of major histocompatibility complex class I molecules in cellular peptide processing. Eur J Immunol 1992;22:655-659.
52. 52. Rammensee HG, Falk K, Rötzschke O. Peptides naturally presented by MHC class I molecules. Annu Rev Immunol 1993;11:213-244.
53. 53. Kisselev AF, Akopian TN, Woo KM, Goldberg AL. The sizes of peptides generated from protein by mammalian 26 and 20 S proteasomes. Implications for understanding the degradative mechanism and antigen presentation. J Biol Chem 1999;274:3363-3371.
54. 54. Shimbara N, et al. Double-cleavage production of the CTL epitope by proteasomes and PA28: role of the flanking region. Genes to Cells 1997;2:785-800.
55. 55. Gaczynska M, Rock KL, Goldberg AL. γ-interferon and expression of MHC genes regulate peptide hydrolysis by proteasomes. Nature 1993;365:264-267.
56. 56. Driscoll J, Brown MG, Finley D, Monaco JJ. MHC-linked LMP gene products specifically alter peptidase activities of the proteasome. Nature 1993;365:262-264.
57. 57. Aki M, et al. Interferon-γ induces different subunit organizations and functional diversity of proteasomes. J Biochem 1994;115:257-269.
58. 58. Ustrell V, Pratt G, Rechsteiner M. Effects of interferon γ and major histocompatibility complex-encoded subunits on peptidase activities of human multicatalytic proteases. Proc Natl Acad Sci USA 1995;92:584-588.
59. 59. Boes B, Hengel H, Ruppert T, Multhaup G, Koszinowski UH, Kloetzel PM. Interferon-γ stimulation modulates the proteolytic activity and the cleavage site preference of 20S mouse proteasomes. J Exp Med 1994;179:901-909.
60. 60. Kuckelkorn U, Frentzel S, Kraft R, Kostka S, Groettrup M, Kloetzel PM. Incorporation of major histocompatibility complex-encoded subunits LMP2 and LMP7 changes the quality of the 20S proteasome polypeptide processing products independent of interferon-γ. Eur J Immunol 1995;25:2605-2611.
61. 61. Groettrup M, et al. The interferon-γ-inducible 11S regulator (PA28) and the LMP2/LMP7 subunits govern the peptide production by the 20S proteasome in vitro. J Biol Chem 1995;270:23808-23815.
62. 62. Eleuteri AM, Kohanski RA, Cardozo C, Orlowski M. Bovine spleen multicatalytic proteinase complex (proteasome). Replacement of X, Y, and Z subunits by LMP7, LMP2, and MECL1 and changes in properties and specificity. J Biol Chem 1997;272:11824-11831.
63. 63. Niedermann G, et al. Potential immunocompetence of proteolytic fragments produced by proteasomes before evolution of the vertebrate immune system. J Exp Med 1997;186:209-220.
64. 64. Groll M, et al. Structure of 20S proteasome from yeast at 2.4 Å resolution. Nature 1997;386:463-471.
65. 65. Arnold D, Driscoll J, Androlewicz M, Hughes E, Cresswell P, Spies T. Proteasome subunits encoded in the MHC are not generally required for the processing of peptides bound by MHC class I molecules. Nature 1992;360:171-174.
66. 66. Momburg F, et al. The proteasome subunits encoded by the major histocompatibility complex are not essential for antigen presentation. Nature 1992;360:174-177.
67. 67. Yewdell J, Lapham C, Bacik I, Spies T, Bennink J. MHC-encoded proteasome subunits LMP2 and LMP7 are not required for efficient antigen presentation. J Immunol 1994;152:1163-1170.
68. d in proteasome subunit LMP2-and LMP7-deficient cells. Eur J Immunol 1994;24:1863-1868.
69. 69. Cerundolo V, Kelly A, Elliott T, Trowsdale J, Townsend A. Genes encoded in the major histocompatibility complex affecting the generation of peptides for TAP transport. Eur J Immunol 1995;25:554-562.
70. + proteasomes are required for the presentation of specific antigens to cytotoxic T lymphocytes. Curr Biol 1995;5:923-930.
71. 71. Van Kaer L, et al. Altered peptidase and viral specific T cell response in LMP2 mutant mice. Immunity 1994;1:533-541.
72. 72. Fehling HJ, et al. MHC class I expression in mice lacking the proteasome subunit LMP-7. Science 1994;265:1234-1237.
73. 73. Dick TP, et al. Coordinated dual cleavages induced by the proteasome regulator PA28 lead to dominant MHC ligands. Cell 1996;86:253-262.
74. 74. Akopian TN, Kisselev AF, Goldberg AL. Processive degradation of proteins and other catalytic properties of the proteasome from Thermoplasma acidophilum. J Biol Chem 1997;272:1791-1798.
75. 75. Hendil KB, Khan S, Tanaka K. Simultaneous binding of PA28 and PA700 activators to 20 S proteasomes. Biochem J 1998;332:749-754.
76. 76. Dick TP, et al. The making of the dominant MHC class I ligand SYFPEITHI. Eur J Immunol 1998;28:2478-2486.
77. 77. Stoltze L, Dick TP, Deeg M, Pommerl B, Rammensee HG, Schild H. Generation of the vesicular stomatitis virus nucleoprotein cytotoxic T lymphocyte epitope requires proteasome-dependent and -independent proteolytic activities. Eur J Immunol 1998;28:4029-4036.
78. 78. Shimbara N, et al. Contribution of proline residue for efficient production of MHC class I ligands by proteasomes. J Biol Chem 1998;273:23062-23071.
79. 79. Craiu A, Akopian T, Goldberg A, Rock KL. Two distinct proteolytic processes in the generation of a major histocompatibility complex class I-presented peptide. Proc Natl Acad Sci USA 1997;94:10850-10855.
80. 80. Bogyo M, McMaster JS, Gaczynska M, Tortorella D, Goldberg AL, Ploegh H. Covalent modification of the active site threonine of proteasomal β subunits and the Escherichia coli homolog HslV by a new class of inhibitors. Proc Natl Acad Sci USA 1997;94:6629-6634.
81. 81. Fenteany G, Standaert RF, Lane WS, Choi S, Corey EJ, Schreiber SL. Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin. Science 1995;268:726-731.
82. 82. Beninga J, Rock KL, Goldberg AL. Interferon-γ can stimulate post-proteasomal trimming of the N terminus of an antigenic peptide by inducing leucine aminopeptidase. J Biol Chem 1998;273:18734-18742.
83. 83. Geier E, et al. A giant protease with potential to substitute for some functions of the proteasome. Science 1999;283:978-981.
84. 84. Snyder HL, Yewdell JW, Bennink JR. Trimming of antigenic peptides in an early secretory compartiment. J Exp Med 1994;180:2389-2394.
85. 85. Elliot T, Willis A, Cerundolo V, Townsend A. Processing of major histocompatibility class I-restricted antigens in the endoplasmatic reticulum. J Exp Med 1995;181:1481-1491.
86. 86. Snyder HL, Bacik I, Yewdell JW, Behrens TW, Bennink JR. Promiscuous liberation of MHC-class I-binding peptides from the C termini of membrane and soluble proteins in the secretory pathway. Eur J Immunol 1998;28:1339-1346.
87. 87. Kaufman J, Wallny HJ. Chicken MHC molecules, disease resistance and the evolutionary origin of birds. Curr Top Microbiol Immunol 1996;212:129-141.
88. 88. Frumento G, Harris PE, Gawinowicz MA, Suciu-Foca N, Pernis B. Sequence of a prominent 16-residue self-peptide bound to HLA-B27 in a lymphoblastoid cell line. Cell Immunol 1993;152:623-626.
89. 89. Urban RG, et al. A subset of HLA-B27 molecules contains peptides much longer than nonamers. Proc Natl Acad Sci USA 1994;91:1534-1538.
90. b) associated with unusually long peptides: implications for antigen processing and presentation. Proc Natl Acad Sci USA 1994;91:4145-4149.
91. 91. Van Endert PM. Peptide selection for presentation by HLA class I: a role for the human transporter associated with antigen processing? Immunol Res 1996;15:265-279.
92. 92. Momburg F, Hämmerling GJ. Generation and TAP-medialed transport of peptides for major histocompatibility complex class I molecules. Adv Immunol 1998;68:191-256.
93. 93. Schoenhals GJ, et al. Retention of empty MHC class I molecules by tapasin is essential to reconstitute antigen presentation in invertebrate cells. EMBO J 1999;18:743-753.
94. 94. Ohno S. To be or not to be a responder in T-cell responses: ubiquitous oligopeptides in all proteins. Immunogenetics 1991;34:215-221.
95. 95. Kasahara M. What do the paralogous regions in the genome tell us about the origin of the adaptive immune system? Immunol Rev 1998;166:159-175.
96. 96. Hughes AL, Hughes MK. Self peptides bound by HLA class I molecules are derived from highly conserved regions of a set of evolutionarily conserved proteins. Immunogenetics 1995;41:257-262.